Adial Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Adial Pharmaceuticals has a total shareholder equity of $6.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $6.7M and $562.7K respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$5.03m |
Equity | US$6.12m |
Total liabilities | US$562.73k |
Total assets | US$6.68m |
Recent financial health updates
Recent updates
Adial Clinical Trial: A Fluff Or A Win?
Aug 22Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01
Aug 16Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst
Jun 21Adial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidate
Jan 11Adial Pharmaceuticals inks stock purchase agreement with Keystone Capital
Nov 25Financial Position Analysis
Short Term Liabilities: ADIL's short term assets ($5.3M) exceed its short term liabilities ($562.7K).
Long Term Liabilities: ADIL has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: ADIL is debt free.
Reducing Debt: ADIL had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ADIL has sufficient cash runway for 10 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: ADIL is forecast to have sufficient cash runway for 8 months based on free cash flow estimates, but has since raised additional capital.